AHA: Chevron Ruling Could Undermine J&J’s 340B Rebate Model

By Maaisha Osman / August 30, 2024 at 1:54 PM
The American Hospital Association is pressing the Health Resources and Services Administration (HRSA) to slap civil monetary penalties on Johnson & Johnson for shifting to a new rebate model for 340B drugs, and told Inside Health Policy the Supreme Court’s recent decision to ax the Chevron principle hurts rather than helps J&J's stance. The comments come as health industry lawyers have widely speculated the high court’s decision to get rid of its Chevron deference to agencies’ interpretation...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.